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Abstract
Introduction Platelet aggregation may contribute to the
pathogenesis of systemic sclerosis: following activation,
platelets release significant amounts of serotonin – which
promotes vasoconstriction and fibrosis, and further enhances
aggregation. The C+1354T polymorphism in the exonic region
of the serotonin 2A receptor gene determining the His452Tyr
substitution was associated with blunted intracellular responses
after serotonin stimulation, and may have a role in susceptibility
to scleroderma.
Methods One hundred and fifteen consecutive systemic
sclerosis patients and 140 well-matched healthy control
individuals were genotyped by sequence-specific primer-PCR
for the His452Tyr substitution of the serotonin 2A receptor gene,
and associations were sought with scleroderma and its main
clinical features. The functional relevance of the His452Tyr
substitution was also assessed by evaluating the aggregation of
platelet-rich plasma from His452/His452 and His452/Tyr452 healthy
individuals after stimulation with adenosine diphosphate ±
serotonin.
Results The T allele of the C+1354T polymorphism was
underrepresented in scleroderma patients compared with
control individuals (5.2% versus 12.4%, P < 0.001, chi-square
test and 1,000-fold permutation test) and its carriage reduced
the risk for systemic sclerosis (odds ratio = 0.39, 95%
confidence interval = 0.19 to 0.85, P < 0.01). Platelets from
His452/Tyr452  healthy subjects more weakly responded to
serotonin stimulation compared with platelets from His452/
His452 individuals (3.2 ± 2.6-fold versus 9.6 ± 8.6-fold increase
in aggregation, P = 0.017 by Kolmogorov–Smirnov test and P
= 0.003 after correction for baseline adenosine diphosphate-
induced aggregation values).
Conclusion The His452Tyr substitution may influence
susceptibility to systemic sclerosis by altering platelet
aggregation in response to serotonin.
Introduction
Systemic sclerosis (SSc) is a complex connective tissue dis-
ease characterised by fibrosis of the skin and internal organs,
widespread vasculopathy and abnormalities of the immune
system [1]. Whilst the deposition of collagen is the ultimate
hallmark of the disease [2], vascular injury and activation are
primary events in the pathogenesis of SSc that may sustain the
fibrotic process from the earliest phases of the disease [2,3].
Amongst the vascular alterations described in SSc patients,
perturbations in platelet homeostasis have long been recog-
nised [4]. Platelets from SSc patients show an activated phe-
notype [5,6] and highly respond to a variety of aggregating
stimuli [7], releasing biomolecules with vasoactive, inflamma-
tory, mitogenic and profibrotic properties [8]. Platelets are a
rich source of serotonin (5-hydroxitrpitamine (5-HT)) [9] – a
powerful mediator with a wide array of functions, ranging from
vasoconstriction in damaged vessels [10], mitogenesis of
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vascular smooth muscle cells [11] and fibroblasts [12], to the
activation of platelets themselves [13,14]. Increased concen-
trations of 5-HT were found in plasma from SSc patients [15],
and the depletion of intraplatelet 5-HT concentrations was
also observed in these subjects [16], reflecting both the
release of 5-HT from intracellular stores and platelets' persist-
ent activation.
The 5-HT functions are mediated by a superfamily of seven
related G-coupled receptors (5-HTR1 to 5-HTR7) [17], but it is
the interaction with the serotonin 2A receptor (5-HTR2A) that
accounts for most of the detrimental profibrotic, vasoconstric-
tive, mitogenic and proaggregating activities of 5-HT [10-14].
The 5-HTR2A gene is located at 13q14-q21, and several single
nucleotide polymorphisms (SNPs) have been identified within
this region, a few of which determine amino acid substitutions
and may thus be relevant from a functional point of view [18].
Amongst these substitutions, one of the most well character-
ised is the nonconservative C/T transition at position +1,354
of the third exon of the 5-HTR2A gene (C+1354T, rs6314) that
determines a His452Tyr substitution in the C-terminal region of
the receptor [19]. This relatively abundant substitution has var-
iedly been associated with several psychiatric disorders [20]
and may influence 5-HT responses by destabilising the intrac-
ellular signal, reducing the activation of G-dependent phos-
pholipases C and D [21]. These events may account for the
described reduced mobilisation of intracellular calcium of
platelets from subjects with the His452Tyr substitution [22],
and may eventually lead to a blunted platelet aggregation.
In the present study we first explored a possible association
between the C+1354T SNP of the 5-HTR2A gene and SSc,
and we then further clarified its functional role by evaluating
platelet aggregation in response to the costimulation with ADP
and 5-HT [14] in healthy subjects with either one of the vari-
ants of the 5-HTR2A gene.
Materials and methods
Patient selection
One hundred and fifteen consecutive unrelated Italian SSc
patients referred to our outpatient clinic were included. All of
the patients fulfilled the classification criteria proposed by the
American College of Rheumatology [23], and were catego-
rised as having limited cutaneous SSc or diffuse cutaneous
SSc according to LeRoy and colleagues [24]. Disease onset
was determined by the patient's recall of the first non-Raynaud
symptom clearly attributable to scleroderma [25]. The
patients' autoantibody profile was also determined by review-
ing the patients' medical records. Antinuclear antibodies were
determined by indirect immunofluorescence on Hep2 cells
(Kallestad, Chaska, MN, USA) using a standardised technique
[26]. Extractable nuclear antigens were determined by a com-
mercial ELISA (Diamedix, Miami, FL, USA). The presence of a
reduced forced vital capacity (<70% of predicted), of a
reduced diffusing capacity for carbon monoxide (<70% of pre-
dicted) or of an increased right-ventricular systolic pressure on
echo (≥ 40 mmHg) was also assessed.
One hundred and forty healthy ethnically matched, sex-
matched and age-matched subjects were also included as
control individuals (case-to-control ratio, 1:2).
All of the patients and all of the controls gave their written con-
sent for the present research. The protocols of the study as
well as of the functional study described below were approved
by the ethic committee of our institution, and are in compliance
with the Declaration of Helsinki.
Sequence-specific primer-PCR for 452His/452Tyr
Ten millilitres of blood were collected into tubes containing
sodium citrate. Genomic DNA was isolated with the DNA Iso-
lation Kit for Mammalian Blood (Roche Diagnostics, Indianap-
olis, IN, USA). To detect the C+1354T SNP, the 5HTR2A gene
was amplified using PCR. In brief, a set of primers was
designed to encompass the C+1354T polymorphic site in the
5HTR2A  gene (forward primer, 5'-AGCCAACTTCAAAT-
GGGACA-3' and reverse primer, 5'-CACACACAGCTCAC-
CTTTTCA-3'). The PCR reaction was performed using 100 ng
genomic DNA, 10 pM each primer, 1.5 mM MgCl2, 2.5 mM
dNTPs and 1 U Euro Taq (Euro Clone, Milano, Italy) in a final
volume of 25 μl. PCR amplification was initiated at 96°C for 5
minutes and was performed for 40 cycles, each consisting of
30 seconds at 96°C, 45 seconds at 58°C and 45 seconds at
72°C. A final elongation step of 5 minutes at 72°C was added.
Sequencing
All of the PCR products were sequenced. Prior to sequencing,
the unincorporated dNTPs and primer were removed by
ExoSAP-IT (USB Corporation, Cleveland, OH, USA) at 37°C
for 15 minutes, after which the enzymes were deactivated by
incubation at 80°C for 15 minutes. Samples were sequenced
in both directions on an Applied Biosystems 3100 Genetic
Analyzer using the Big-Dye Terminator Cycle Sequencing
Reaction Kit (Applied Biosystems, Foster City, CA, USA). The
cycling conditions were 25 cycles of denaturation at 96°C for
10 seconds, annealing at 50°C for 5 seconds and extension
at 60°C for 4 minutes.
Platelet aggregation
Blood samples from 452His/452Tyr and 452Tyr/452Tyr healthy
nonsmoker individuals were obtained for the functional study;
none of these subjects was receiving steroids or antiaggrega-
tion therapy. Whole blood, anticoagulated with sodium citrate
(final concentration, 3.8%), was immediately centrifuged at
130 × g for 15 minutes in order to obtain platelet-rich plasma.
A subsequent centrifugation at 1,050 × g  for 15 minutes
allowed one to obtain platelet-poor plasma, used to set the
100% light transmission of the instrument. Then 250 μl plate-
let-rich plasma was warmed at 37°C for 3 minutes, and the
agonist was added. Platelet aggregation was performed on aAvailable online http://arthritis-research.com/content/10/5/R103
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Chrono-Log Aggregometer (Mascia-Brunelli, Milano, Italy)
with ADP (Sigma-Aldrich Corp, Milano, Italy) in a plain
Tyrode's solution containing 2 mM CaCl2, 1 mM MgCl2, 0.1%
dextrose, 0.35% BSA, 0.05 U/ml apyrase, pH 7.35, at a final
concentration of 1 μM, or with ADP + 5-HT (Sigma-Aldrich
Corp.) both at a 1 μM final concentration. Platelet aggregation
was recorded for 3 minutes and the maximum light transmis-
sion in this period was measured. The response to 5-HT was
then calculated as the fold increase in 5-HT-induced aggrega-
tion with respect to the aggregation observed after stimulation
with ADP alone.
In the present work the decision was made not to replicate the
functional study in SSc patients. This decision was mainly due
to different reasons. Firstly, all of our patients were being
treated with a combination of drugs that may alter platelet
function (for example, low-dose aspirin, nifedipine, chronic
intravenous iloprost), and thus it would have been unethical to
interrupt their ongoing therapy. Secondly, SSc platelets show
an activated phenotype that that would have been a significant
confounding factor in the analysis of platelet function [5-7].
Statistical analysis
Association study
The distribution of the C+1354T genotypes was tested for
Hardy–Weinberg equilibrium with the goodness-of-fit chi-
squared test both in patients and in control individuals.
The distribution of the C+1354T genotypes and alleles
between control individuals and SSc subjects was tested by
the chi-squared test or Fisher's exact test when necessary.
Odds ratios and their relative 95% confidence intervals were
also calculated from 2 × 2 contingency tables. Statistical sig-
nificance was also evaluated using a 1,000-fold permutation
test.
Genetic-association studies might be flawed by the possibility
of false-positive results, even in the presence of statistically
significant findings – that is, according to the definition of
Wacholder and colleagues [27], the false-positive report prob-
ability (FPRP). The FPRP values are calculated by the follow-
ing formula: FPRP = 1/{1 + [π/(1 - π)] [(1 - β)/α]}, where π is
the prior probability that the association is true, α is the type I
error probability and β is the type II probability to detect the
association under the experimental conditions.
In the present context, α was set to the observed P value while
π was set from 0.001 up to relatively high values (0.5 – 1),
given that only five SNPs within the 5-HTR2A gene determine
amino acid substitutions and may thus be functionally relevant,
and the C+1354T SNP indeed alters platelet function in vitro
(see reference [22] and the results below).
Finally, the statistical power (1 - β) was calculated by the PS
Program [28], and it was defined as the power to detect an
odds ratio of 1.5, 1.75 or 2 for the carriers of the 452His/452Tyr
substitution and to detect an odds ratio of 1 for the homozy-
gote with the common variant, with an α level equal to the
observed P value.
The FPRP values for the present study were then reported in
a table with the corresponding π and odds ratio values; FPRP
values < 0.5 are then highlighted. These values are considered
adequate in small exploratory studies on genetic associations
[27] – given that some estimates of the overall FPRP in the
molecular epidemiology literature have been up to 0.95 [29].
Functional study
The 5-HT-to-ADP aggregation rate in 452His/452His and
452His/452Tyr healthy subjects was compared by the nonpara-
metric Kolmogorov–Smirnov test and was then verified by lin-
ear regression. As platelet-induced aggregation displays a
ceiling effect, the magnitude of the dependent variable (5-HT-
to-ADP aggregation ratio) may be correlated with the variance
of baseline (ADP-induced) aggregation, thus violating the
assumption of homoscedasticity [30]. Linear regression was
thus conducted by the weighted least-squares analysis proce-
dure, with the ADP-induced aggregation as the weight varia-
ble and with gender as an additional covariate.
All of the statistical procedures were carried out with the
SPSS version 15.0 software (SPSS Inc., Chicago, IL, USA). P
< 0.05 was considered significant.
Continuous values are expressed as the mean ± standard
deviation – except for skewed distributions (skewness <-2 or
skewness >2), where the median and interquartile range are
reported.
Results
The demographic and clinical characteristics of the patients
are reported in Table 1. The genotypes of the C+1354T SNP
respected the Hardy–Weinberg equilibrium both in patients
and in control individuals. The overall minor allele frequency
was 0.092.
Association study
As reported in Table 2, the CT genotypes (452His/452Tyr heter-
ozygosity) and the TT genotypes (452Tyr/452Tyr homozygosity)
of the C+1354T SNP were underrepresented in SSc patients
compared with control individuals (χ2 = 7.102, two degrees of
freedom, P = 0.011). Similarly, a decreased frequency of the
T allele was observed in SSc patients (χ2 = 7.308, one degree
of freedom, P < 0.001). All of the results were confirmed after
the 1,000-fold permutation test (P < 0.05 and P < 0.001 for
genotypes and alleles, respectively). Overall, 452His/452Tyr and
452Tyr/452Tyr individuals had a threefold reduction in the risk
for SSc compared with 452His/452His individuals (odds ratio =
0.39, 95% confidence interval = 0.19 to 0.85, P < 0.01).Arthritis Research & Therapy    Vol 10 No 5    Beretta et al.
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The FPRP values of the association between SSc and the
452His/452Tyr substitution are reported in Table 3 with high-
lighted noteworthiness values at the 0.5 level.
Robust associations with clinical variables were difficult to cal-
culate owing to the low prevalence of the rarer allele of the
C+1354T SNP in SSc patients; however, from an exploratory
point of view, the His452Tyr substitution was not associated
with any of the following: the disease subset, the anticorpal
status, age at the onset of the disease, past history of digital
ulcers, the forced viral capacity, the diffusing capacity for car-
bon monoxide or the right systolic ventricular pressure.
Platelet aggregation
Platelets from 15 healthy subjects (eight 452His/452His
homozygous subjects, seven 452His/452Tyr heterozygous sub-
jects) had poor aggregating responses after stimulation with
ADP alone (median, 11.8%; interquartile range, 5.4% to 25%
light transmission). Aggregating responses were markedly
increased after costimulation with 5-HT and ADP (median,
3.8-fold increase; interquartile range, 2.9-fold to 8.6-fold) with
respect to the stimulation observed with ADP alone (Figure 1).
These data are consistent with previous studies reported in
the literature [14].
The ADP-induced baseline aggregation, age, platelet count
and gender distribution did not differ between 452His/452His
individuals and 452His/452Tyr individuals. The 452His/452Tyr
heterozygous subjects had blunted responses to 5-HT stimu-
lation compared with 452His/452His homozygous subjects
(mean, 3.2 ± 2.6-fold versus 9.6 ± 8.6-fold increase, P =
0.017). The functional significance of the His452Tyr substitu-
tion was better assessed by linear regression analysis,
weighted for ADP-induced platelet aggregation; by this proce-
dure, it was confirmed at a highly significant level that the
His452Tyr substitution of the 5-HTR2A  dampened platelet
aggregation in response to 5-HT (Figure 2, P = 0.003). The
regression equation of the final model with adjusted R2 = 0.98
had an almost perfect fit: 5-HT-to-ADP-response ratio (fold
increase) = 4.995 - (0.019 × ADP-induced aggregation) -
(1.148 × gender) - (1.192 × His452Tyr substitution) (where
zero represents females and/or 452His, and one represents
males and/or 452Tyr).
Discussion
Owing to the evidence of involvement of vasculopathy in the
pathogenesis of SSc [2,3], much research has been carried
out to elucidate the role of genetic variants of biomolecules
with vascular activities in scleroderma patients [31-37].
Despite the number of studies indicating a role for platelets
and the 5-HT system in the onset of or in the maintenance of
Table 1
Demographic and clinical characteristics
Variable Value (n = 115)
Females 108 (93.9)
Limited cutaneous systemic sclerosis 84 (73)
Autoantibody
Antinuclear antibody without specific pattern 19 (16.5)
Anticentromere antibody 44 (38.3)
Antitopoisomerase I antibody 50 (43.5)
Age at onset (years) 43.4 ± 12.6
Mean follow-up (years) 14.6 ± 8.7
Forced viral capacity <70% predicted 27 (23.4)
Diffusing capacity for carbon monoxide <70% 
predicted
82 (71.4)
Right systolic ventricular pressure ≥ 40 mmHg 22 (19.1)
Oesophageal involvement 110 (96.2)
Past history of digital ulcers 63 (54.7)
Data presented as n (%) or as the mean ± standard deviation.
Table 2
Genotype and allele distribution of the C+1354T single nucleotide polymorphism in patients with systemic sclerosis and in matched 
control individuals
C+1354T single nucleotide polymorphism Systemic sclerosis patients (n = 115) Control individuals (n = 140)
Genotype*
CC 103 (89.6) 108 (77.1)
CT 12 (10.4) 30 (21.4)
TT 0 (0) 2 (1.4)
Allele**
C 218 (94.8) 246 (87.6)
T 12 (5.2) 34 (12.4)
Data presented as n (%).*P < 0.05. **P < 0.01 (chi-square test).Available online http://arthritis-research.com/content/10/5/R103
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the vascular damage in SSc [4], however, no genetic research
has so far been conducted in this field. The present study was
thus undertaken to analyse, for the first time, the distribution
and the functional role of a naturally occurring amino acidic
substitution of the 5-HTR2A gene in a population of Italian SSc
patients.
Our results indicate that the C/T transition at position +1,354
of the third exon of the 5-HTR2A gene [19] is associated with
a threefold reduction in the risk for SSc. This effect could be
linked to a blunted platelet aggregation in response to the
serotoninergic stimulus in 452His/452Tyr heterozygotes com-
pared with 452His/452His homozygotes, as indicated by our ex
vivo study (Figure 2). This observation is in full accordance
with the finding that the His452tyr substitution in the 5-HTR2A
gene is accompanied by a reduced mobilisation of platelet
intracellular calcium after stimulation with 5-HT [22].
The 5-HT concentrations are increased in plasma samples
from SSc [16] as a consequence of platelet activation that fol-
lows the binding to collagen type I and type III exposed under
the damaged endothelium, which is also favoured by T-
dependent immunological mechanisms [4]. It is thus possible
to speculate that the carriage of the C+1354T SNP dampens
the mechanisms that sustain platelet aggregation and SSc
vasculopathy [2,4], once they have been triggered via other
biological pathways. This hypothesis would confirm previous
findings indicating that 5-HT is more relevant in the mainte-
nance of the vascular phenomena that underlie the pathogen-
esis of SSc, rather than in determining their onset [38]. We
cannot, however, exclude the His452Tyr substitution possibly
having a role in SSc susceptibility by acting on different cellu-
lar types that express the 5-HTR2A gene (for example, fibrob-
Table 3
False-positive report probabilities under different scenarios
Prior probability Odds ratio
1.5 1.75 2
0.1 0.48 0.29 0.19
0.05 0.66 0.46 0.33
0.01 0.91 0.82 0.72
0.001 0.99 0.98 0.97
False-positive report probability values are presented for the 
association between the C+1354T single nucleotide polymorphism 
and systemic sclerosis in our population. Different ranges of values 
are reported in relation to the prior probability values and the power 
to detect different odds ratios for 452His/452Tyr individuals compared 
with 452His/452His subjects, with α = 0.009. Data in italics are 
reported noteworthy false-positive report probability values at the 0.5 
level.
Figure 1
Platelet aggregation induced by ADP and serotonin Platelet aggregation induced by ADP and serotonin. Left panel: aggregation induced by 1 μM ADP + 1 μM buffer solution (plain Tyrode's solution 
(PT)). Right panel: aggregation induced by 1 μM ADP + 1 μM serotonin (5-HT). The ratio between the two highest light transmission percentages is 
the 5-HT-to-ADP response ratio (in the example, 68.5/21.2 = 3.23-fold increase).Arthritis Research & Therapy    Vol 10 No 5    Beretta et al.
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lasts or vascular smooth muscle cells), regardless of its effect
on 5-HT-induced platelet aggregation. Indeed, Hazelwood
and Sanders-Bush also described a reduced intracellular sig-
nalling capacity in murine fibroblasts expressing the His452Tyr
substitution after stimulation with 5-HT [21].
The potential limitations of our study are the relatively small
sample size and the lack of a replicate population. We feel
confident that the evidence demonstrating the functional rele-
vance of the His452Tyr substitution, however, makes our find-
ings modestly prone to false positive results. The significance
of our results can also be gauged considering the FPRP val-
ues we obtained under different scenarios (Table 3). Whilst no
significant FPRP values were observed for prior probabilities ≤
0.01, which were originally advocated as an adequate setting
for a gene with functional data [27], it may be argued that
these prior probability values, or conversely the FPRP 0.5
threshold, may be too penalising for an exploratory study such
as ours. Even if no single point mutation is therefore likely to
determine the onset of a multifactorial disease such as SSc,
our results indicate that the C+1354T SNP is a suitable SNP
for further research in the scleroderma field and that it may be
worthy of inclusion in association studies based on a candi-
date gene approach [39]. Of particular interest would also be
the study of epistatic interactions or intermediate quantitative
trait analysis between this mutation and other genetic variants
of the 5-HT2A gene or other serotonin receptors, such as the
5-HT3A gene that was also found to play a role in the fibrotic
process of SSc [40,41]. Finally, the demonstration that the
C+1354T SNP is indeed associated with a reduced platelet
aggregation after stimulation with 5-HT may have practical
implications besides SSc – that is, in other diseases where the
serotoninergic system is involved.
Conclusion
We provide evidence that the His452Tyr substitution of the 5-
HT2Areceptor, determined by the C+1354T SNP of the corre-
sponding gene, is functionally relevant to platelet aggregation
in vitro, dampening the responses to the serotoninergic stim-
ulus. The functional relevance of this polymorphism may
explain the inverse association (for example, protective effect)
we observed in a population of Italian SSc patients. The
C+1354T SNP is therefore worth inclusion in a panel of can-
didate genes for future association studies in the SSc field.
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